CHEMO PHARMA LABORATORIES LTD Q4 RESULTS
Sun Pharma Q4 Results: India's largest drugmaker reports net profit of Rs 1,985 crore
Sun Pharma, India's largest drugmaker, on Friday, reported a consolidated net profit of Rs 1,984.47 crore for the quarter ended March 31, 2023, against a loss of Rs 2,277.25 crore in the same period last year. The profit was, however, lower sequentially as it stood...
Sun Pharma posts loss of Rs 2,277 cr in Q4 due to one-time exceptional loss of Rs 3,936 cr
Sun Pharmaceutical Industries on Monday said its consolidated net loss for the March quarter came in at Rs 2,277.25 crore compared to a profit of Rs 894.15 crore in the same quarter last year. Total revenue from operations increased 10.83 per cent year-on-year...
Sun Pharma Q4 results: Net profit declines 37% to Rs 399 cr
Pharma major Sun Pharmaceutical Industries on Wednesday reported a 37.12 per cent decline in its consolidated net profit to Rs 399.84 crore for the quarter ended March 2020, mainly on account of one time exceptional loss. The company had posted a net profit of Rs 635.88 crore in the same pe...
Watch: Dr Reddy's Labs Q4 profit falls 3% to Rs 302 crore
Drug firm Dr Reddy's Laboratories on Tuesday reported a 3.29 per cent fall in its consolidated net profit to Rs 302.2 crore for the fourth quarter ended March 31, 2018, mainly on account of continuing headwinds in the US. The company had posted a net profit of Rs 312.5 crore for the correspon...
Watch: Dr Reddy's Labs Q3 consol PAT at Rs 334 crore
Pharma major Dr Reddy's Laboratories on Thursday reported a 28.86 per cent YoY drop in net profit at Rs 334 crore for the December quarter. The company said the numbers were impacted by one-time charge of Rs 93 crore due to deferred tax on assets and liabilities of the US entity. The company had r...
Watch: Cipla posts Q4 profit of Rs 179 crore
Cipla Limited, India's second-biggest drugmaker by market capitalisation, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates. Net profit came in at 1.79 billion rupees for the quarter ended March 31, compared with a loss of 617.9 million rupees in the year-ago quarter, the company s...
Sun Pharma net profit drops 13.6% in Q4
Sun Pharma on Friday reported a 13.59 per cent drop in consolidated net profit at Rs 1,223.71 crore for the March quarter.Sun Pharma net profit drops 13.6% in Q4
Watch: ET Headlines @ 12 noon
Watch the video for the latest updates and developments in and around the business world with ET Now.Watch: ET Headlines @ 12 noon
Sun Pharma consolidated PAT at Rs 1, 710 cr
The consolidated PAT of Sun Pharma stood at Rs Rs 1, 710 crore, lower than ET Now estimate of Rs 1, 905 crore.Sun Pharma consolidated PAT at Rs 1, 710 cr
Aurobindo Pharma consolidated PAT up 39.3% YoY
Aurobindo Pharma consolidated PAT stood at Rs 563 cr vs Rs 404 cr, up 39.3% YoY.Aurobindo Pharma consolidated PAT up 39.3% YoY
Ranbaxy beats, Lupin lags estimates
Ranbaxy Laboratories rose 6.1 per cent on Tuesday, after the pharma major reported a net profit of Rs 478 crore for the quarter ended September 30, which was higher than Street estimates. The pharma major reported a net loss of Rs 454 crore in the corresponding quarter of last fiscal. Lupin, however, lagged estima
Sun Pharma Q3 net profit jumped nearly 4 times
Sun Pharmaceuticals, India's largest pharma company, posted a net profit of Rs 1,420 crore for the quarter ending December 30, 2015, up nearly four times YoY.Sun Pharma Q3 net profit jumped nearly 4 times
Don’t expect Q4 results to be good: Silverdale Cap
ET Now caught up with Sanjay Guglani, CIO, Silverdale Capital, for his views on the Q4 earnings' expectations, markets and certain sectors and stocks. Here's the excerpts.Don’t expect Q4 results to be good: Silverdale Cap
Dr Reddy's Q2 net profit down 17 per cent at Rs 574.1 crore
The pharma major’s global generics business grew by just 9% against market estimate of 15-20% growth. Its revenues from Europe was down 19% while those from Russia fell 13%.Dr Reddy's Q2 net profit down 17 per cent at Rs 574.1 crore
Q4 results: Sun Pharma, Hindalco, ONGC, Cipla, Bhel
Sun Pharmaceutical Industries, India's third-largest drugmaker by revenue, reported a 57 percent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.Q4 results: Sun Pharma, Hindalco, ONGC, Cipla, Bhel
Ranbaxy Laboratories Q4 PAT at Rs 262 crore
Ranbaxy Laboratories Q4 PAT at Rs 262 crore
Sun Pharma Q2 PAT at Rs 320cr vs Rs 598cr, down 46.4% YoY
Sun Pharma Q2 PAT at Rs 320cr vs Rs 598cr, down 46.4% YoY
Load More
